231 related articles for article (PubMed ID: 31473161)
1. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats.
Dutta AK; Santra S; Harutyunyan A; Das B; Lisieski MJ; Xu L; Antonio T; Reith MEA; Perrine SA
Eur J Pharmacol; 2019 Nov; 862():172632. PubMed ID: 31473161
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
3. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
4. Severe, multimodal stress exposure induces PTSD-like characteristics in a mouse model of single prolonged stress.
Perrine SA; Eagle AL; George SA; Mulo K; Kohler RJ; Gerard J; Harutyunyan A; Hool SM; Susick LL; Schneider BL; Ghoddoussi F; Galloway MP; Liberzon I; Conti AC
Behav Brain Res; 2016 Apr; 303():228-37. PubMed ID: 26821287
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress - A model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies.
Malikowska N; Fijałkowski Ł; Nowaczyk A; Popik P; Sałat K
Brain Res; 2017 Oct; 1673():1-10. PubMed ID: 28797691
[TBL] [Abstract][Full Text] [Related]
6. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
7. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
[TBL] [Abstract][Full Text] [Related]
9. Single prolonged stress: toward an animal model of posttraumatic stress disorder.
Yamamoto S; Morinobu S; Takei S; Fuchikami M; Matsuki A; Yamawaki S; Liberzon I
Depress Anxiety; 2009; 26(12):1110-7. PubMed ID: 19918929
[TBL] [Abstract][Full Text] [Related]
10. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
[TBL] [Abstract][Full Text] [Related]
11. A modified single-prolonged stress model for post-traumatic stress disorder.
Wang W; Liu Y; Zheng H; Wang HN; Jin X; Chen YC; Zheng LN; Luo XX; Tan QR
Neurosci Lett; 2008 Aug; 441(2):237-41. PubMed ID: 18577419
[TBL] [Abstract][Full Text] [Related]
12. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
[TBL] [Abstract][Full Text] [Related]
13. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
15. Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus.
Uniyal A; Singh R; Akhtar A; Bansal Y; Kuhad A; Sah SP
Pharmacol Biochem Behav; 2019 Oct; 185():172763. PubMed ID: 31445955
[TBL] [Abstract][Full Text] [Related]
16. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of morphine in a rat model of post-traumatic stress disorder: Role of hypothalamic-pituitary-adrenal axis and beta- adrenergic system.
Abdullahi PR; Raeis-Abdollahi E; Sameni H; Vafaei AA; Ghanbari A; Rashidy-Pour A
Behav Brain Res; 2020 Oct; 395():112867. PubMed ID: 32827567
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
19. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD.
Yamamoto S; Morinobu S; Fuchikami M; Kurata A; Kozuru T; Yamawaki S
Neuropsychopharmacology; 2008 Aug; 33(9):2108-16. PubMed ID: 17957211
[TBL] [Abstract][Full Text] [Related]
20. Cheonwangbosimdan mitigates post-traumatic stress disorder-like behaviors through GluN2B-containing NMDA receptor antagonism in mice.
Kong CH; Min HS; Jeon M; Kang WC; Park K; Kim MS; Jung SY; Bae HJ; Park SJ; Shin HK; Seo CS; Ryu JH
J Ethnopharmacol; 2024 Aug; 330():118270. PubMed ID: 38685368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
